AZD9291 CAS NO.1421373-65-0

BOC Sciences is committed to supplying cost-effective products and services. We provide AZD9291. AZD9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. It is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. It is used in the treatments of nonsmall-cell lung cancer. More information please visit: www.bocsci.com/azd9291-cas-1421373-65-0-item-467125.html